Tranexamic Acid vs Fractional CO2 Laser in Post-acne Hyperpigmentation
Tranexamic Acid Versus Fractional CO2 Laser in Post-inflammatory Hyperpigmentation in Acne Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Egyptians of both sexes.
- Age > 18.
- Patients who can avoid sun exposure one week after sessions.
- Patients who stopped taking systemic isotretinoin for more than six months.
Exclusion Criteria:
- Pregnancy and lactation.
- Concomitant use of anticoagulants.
- Bleeding disorders.
- Personal or family history of DVT or thromboembolic events.
- Scarring and keloid tendency.
- Active skin infection, active HSV.
- History of photosensitivity or photosensitizing medication.
- Occupational sun exposure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tranexamic acid injection (Kapron)
One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml.
TXA will be prepared under sterile conditions.
Injections will be applied intradermally on hyperpigmented areas at 1cm intervals.
The injection will be repeated every two weeks for three months.
|
One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml.
TXA will prepared under sterile conditions.
Injections will be applied intradermally on hyperpigmented areas at 1cm intervals.
The injection will be repeated every two weeks for three months.
Other Names:
|
|
Active Comparator: Fractional CO2 laser resurfacing
The other side of the face will be randomly assigned to do low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
|
The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measurement of melanin index to assess change of post-acne hyperpigmentation
Time Frame: 3 months
|
the melanin index (MI) average is 1.10 +/-0.29 with higher values showing worse outcome.
It will be measured using reflectance spectrophotometer in order to assess the degree of hyperpigmentation
|
3 months
|
|
Measurement of erythema index to assess change of post-acne hyperpigmentation
Time Frame: 3 months
|
the erythema index (EI) average is 1.29 +/- 0.38 with higher values showing worse outcome.
It will be measured using reflectance spectrophotometer in order to assess the degree of erythema
|
3 months
|
|
Measurement of post-acne hyperpigmentation index to assess change of post-acne hyperpigmentation
Time Frame: 3 months
|
the post-acne hyperpigmentation index (PAHPI) ranges from 6-22 with higher values showing worse outcome.
It is a summation of three scores (Postinflammatory hyperpigmentation(PIH) lesion size, median lesion intensity compared with surrounding skin and the number of PIH lesions).
|
3 months
|
|
Patient satisfaction score to assess change of post-acne hyperpigmentation
Time Frame: 3 months
|
It is a score ranging from 1-4 with improvement 0-25%=1, 26-50%= 2, 51-75%=3 and more than 75%=4 so higher values of patient satisfaction score showing better outcome
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Dermatology 9
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.